Septerna (SEPN) Cash from Investing Activities (2023 - 2026)
Septerna's (SEPN) quarterly Cash from Investing Activities came in at -$23.8 million in Q1 2026, down 388.65% year-on-year from $8.3 million in Q1 2025, and up 87.15% quarter-over-quarter from -$185.3 million in Q4 2025.
Septerna (SEPN) Cash from Investing Activities (2023 - 2026) Analysis & Trends
Septerna's Cash from Investing Activities history runs 4 years deep, the most recent figure standing at -$23.8 million for Q1 2026.
- On a quarterly basis, Cash from Investing Activities fell 388.65% year-over-year to -$23.8 million in Q1 2026; TTM through Mar 2026 was -$248.3 million, a 41.85% decrease from a year earlier, with the FY2025 full-year figure at -$229.4 million, down 42.81% from the prior year.
- Cash from Investing Activities advanced to -$23.8 million in Q1 2026 per SEPN's latest filing, from -$185.3 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $9.6 million in Q1 2024 and bottomed at -$185.3 million in Q4 2025.
- The 4-year median for Cash from Investing Activities is -$18.0 million (2024), against an average of -$41.5 million.
- Across the five-year window, Cash from Investing Activities sank 10653.75% in 2024 and soared 93.52% in 2025, its largest moves.
- Year by year, Cash from Investing Activities stood at -$1.2 million in 2023, then sank by 10653.75% to -$133.2 million in 2024, then tumbled by 39.07% to -$185.3 million in 2025, then surged by 87.15% to -$23.8 million in 2026.
- Per Business Quant, the three latest SEPN Cash from Investing Activities figures stand at -$23.8 million (Q1 2026), -$185.3 million (Q4 2025), and -$38.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,015.37 Bn | 1,015.37 Bn | - | - |
| 4 | BeOne Medicines | 471.39 Bn | 466.59 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 122.52 Bn | 115.28 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 70.33 Bn | 61.58 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Septerna | 1.49 Bn | 1.49 Bn | - | -23.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.82 Mn |
| Mar 31, 2026 | -23.82 Mn |
| Dec 31, 2025 | -185.30 Mn |
| Dec 31, 2025 | -185.30 Mn |
| Sep 30, 2025 | -38.39 Mn |
| Sep 30, 2025 | -38.39 Mn |
| Jun 30, 2025 | -786,000.00 |
| Jun 30, 2025 | -786,000.00 |
| Mar 31, 2025 | -4.87 Mn |
| Mar 31, 2025 | -4.87 Mn |
| Dec 31, 2024 | -133.24 Mn |
| Dec 31, 2024 | -133.24 Mn |
| Sep 30, 2024 | -24.79 Mn |
| Sep 30, 2024 | -24.79 Mn |
| Jun 30, 2024 | -12.13 Mn |
| Jun 30, 2024 | -12.13 Mn |
| Mar 31, 2024 | 9.57 Mn |
| Mar 31, 2024 | 9.57 Mn |
| Dec 31, 2023 | -1.24 Mn |
| Dec 31, 2023 | -1.24 Mn |